Works in Hematological Oncology, 2022, Vol 40, Issue 5
Results: 34
CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 876, doi. 10.1002/hon.3072
- By:
- Publication type:
- Article
Socioeconomic position and clinical outcomes in patients with myelodysplastic syndromes: A population‐based cohort study.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1056, doi. 10.1002/hon.3068
- By:
- Publication type:
- Article
Characteristics and clinical outcomes of patients with ALK‐positive anaplastic large cell lymphoma: Report from the prospective international T‐cell lymphoma project.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 953, doi. 10.1002/hon.3074
- By:
- Publication type:
- Article
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 962, doi. 10.1002/hon.3063
- By:
- Publication type:
- Article
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 906, doi. 10.1002/hon.3066
- By:
- Publication type:
- Article
Clinical significance of MYD88 non‐L265P mutations in diffuse large B‐cell lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 885, doi. 10.1002/hon.3073
- By:
- Publication type:
- Article
Therapeutic management and outcome of patients with advanced systemic mastocytosis treated with midostaurin: A comprehensive real‐life study in the French national healthcare database.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1030, doi. 10.1002/hon.3062
- By:
- Publication type:
- Article
Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 857, doi. 10.1002/hon.3060
- By:
- Publication type:
- Article
Prognostic impact of complex karyotype on post‐transplant outcomes of myelofibrosis.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1076, doi. 10.1002/hon.3058
- By:
- Publication type:
- Article
Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 894, doi. 10.1002/hon.3056
- By:
- Publication type:
- Article
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup>) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 930, doi. 10.1002/hon.3054
- By:
- Publication type:
- Article
Long‐term follow‐up and health‐related quality of life among cancer survivors with stage IEA orbital‐type lymphoma after external photon‐beam radiotherapy: Results from a longitudinal study.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 922, doi. 10.1002/hon.3053
- By:
- Publication type:
- Article
Dual epigenetic agents plus rituximab–gemcitabine–oxaliplatin as salvage treatment in relapsed/refractory diffuse large B‐cell lymphoma patients failure of salvage chemotherapy.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 914, doi. 10.1002/hon.3052
- By:
- Publication type:
- Article
NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 864, doi. 10.1002/hon.3050
- By:
- Publication type:
- Article
D<sub>max</sub>: A simple and reliable PET/CT‐derived new biomarker of lymphoma outcome?
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 843, doi. 10.1002/hon.3049
- By:
- Publication type:
- Article
Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 846, doi. 10.1002/hon.3048
- By:
- Publication type:
- Article
Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1041, doi. 10.1002/hon.3046
- By:
- Publication type:
- Article
Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 999, doi. 10.1002/hon.3045
- By:
- Publication type:
- Article
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 976, doi. 10.1002/hon.3044
- By:
- Publication type:
- Article
Pirarubicin‐based intensive chemotherapy followed by consolidative high‐dose chemotherapies for peripheral T‐cell lymphomas: A noncomparative phase 2 study.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1094, doi. 10.1002/hon.3043
- By:
- Publication type:
- Article
Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 941, doi. 10.1002/hon.3042
- By:
- Publication type:
- Article
Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 987, doi. 10.1002/hon.3041
- By:
- Publication type:
- Article
BCR/ABL1ΔE7‐8‐9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1067, doi. 10.1002/hon.3040
- By:
- Publication type:
- Article
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1105, doi. 10.1002/hon.3039
- By:
- Publication type:
- Article
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1020, doi. 10.1002/hon.3038
- By:
- Publication type:
- Article
Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 835, doi. 10.1002/hon.3037
- By:
- Publication type:
- Article
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 821, doi. 10.1002/hon.3036
- By:
- Publication type:
- Article
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1009, doi. 10.1002/hon.3035
- By:
- Publication type:
- Article
Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1100, doi. 10.1002/hon.3032
- By:
- Publication type:
- Article
A novel start‐loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1109, doi. 10.1002/hon.3023
- By:
- Publication type:
- Article
Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1097, doi. 10.1002/hon.3006
- By:
- Publication type:
- Article
Comparing apples and oranges: The ZUMA‐7, TRANSFORM and BELINDA trials.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1090, doi. 10.1002/hon.3001
- By:
- Publication type:
- Article
Finding a consensus on time‐to‐event endpoints definitions in marginal zone lymphoma: A Delphi method.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1086, doi. 10.1002/hon.2988
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 819, doi. 10.1002/hon.2893
- Publication type:
- Article